Torrent Pharmaceuticals revenue and financials
₹4,710.00Change from previous close: −1.42%Absolute change: −₹68.00
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹139.8B (+21.39% year over year). Net income was ₹21.63B, a net margin of 15.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.39%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.5%
- FY to Mar 2025: 16.6%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 443,120 | 149,897 | 150,606 | 150,119 | 130,998 |
| Current assets | 93,931 | 56,226 | 56,115 | 53,292 | 52,947 |
| Cash and equivalents | 11,172 | 5,735 | 8,351 | 5,085 | 3,984 |
| Short-term investments | 3,723 | 22.8 | 279 | 582 | 5.9 |
| Receivables | 36,846 | 22,480 | 21,863 | 22,300 | 19,137 |
| Inventory | 31,382 | 25,413 | 22,791 | 22,296 | 24,623 |
| Net property, plant and equipment | 53,660 | 38,229 | 35,778 | 34,598 | 32,469 |
| Goodwill | 39,896 | 3,389 | 3,380 | 3,375 | 2,595 |
| Other intangible assets | 244,636 | 42,633 | 45,828 | 50,895 | 35,461 |
| Long-term investments | 994 | 446 | 333 | 711 | 679 |
| Current liabilities | 83,433 | 47,172 | 54,253 | 54,473 | 44,151 |
| Accounts payable | 23,576 | 18,200 | 20,893 | 16,788 | 16,744 |
| Long-term debt | 116,512 | 11,918 | 16,038 | 24,962 | 21,232 |
| Total debt | 150,255 | 32,023 | 40,219 | 53,686 | — |
| Total liabilities | 267,271 | 73,991 | 82,044 | 88,138 | 71,469 |
| Total equity (incl. minority) | 175,848 | 75,907 | 68,562 | 61,981 | 59,530 |
| Retained earnings | 86,439 | 76,307 | 67,908 | 61,159 | 57,739 |
| Minority interest | 91,964 | 0.0 | — | — | — |